Overview

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Status:
NOT_YET_RECRUITING

Trial end date:
2031-10-27

Target enrollment:

Participant gender:

Summary

The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .

Phase:

PHASE2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

belantamab mafodotin
Bortezomib
Cyclophosphamide
Dexamethasone